Advertisement

Topics

Latest "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Stories

19:14 EDT 15th July 2018 | BioPortfolio

Here are the most relevant search results for "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" found in our extensive news archives from over 250 global news sources.

More Information about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent for you to read. Along with our medical data and news we also list CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Clinical Trials, which are updated daily. BioPortfolio also has a large database of CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Companies for you to search.

Showing "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Articles 1–25 of 4,600+

Sunday 15th July 2018

Global Pancreatic Cancer Therapeutics Diagnostics Market Segmented by Therapeutic, by Diagnostic and Geography Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $4250

The global pancreatic cancer therapeutics diagnostics market was valued at USD 2,272.40 million in 2017, and is expected to witness a CAGR 5.6% during 2018 to 2023 henceforth referred to as the forecast period. Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of the cancer deaths and in Europe, pancreatic cancer is the 4th leading cause of death. Accelerati...


Orla’s new patent granted in UK

Orla Protein Technologies Ltd, a leader in the design, engineering and immobilisation of proteins for surface applications, has been granted U.K. patent No. GB2527623 to its novel protein engineering and immobilisation platform (OrlaSURF) for immobilisation of proteins to polymeric surfaces.“This important piece of IP further strengthens our patent portfolio. We have built an exceptionally p...

Saturday 14th July 2018

Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced its intent to appeal the decision made by the U.S. District Court for the District of New Jersey in a preliminary injunction hearing with respect to further sales and commercialization of Dr. Reddy’s ...


Cytran Gets US Patent Covering Anti-Angiogenesis Effects of IM862

The US Patent and Trademark Office has granted Cytran Inc. (Kirkland, WA) a patent for the anti-angiogenesis effects of the their lead drug, IM862...

Friday 13th July 2018

Saudi Arabia Hospital Supplies Market Segmented by Durables, Disposables and Reusables Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $1920

The Saudi Arabia hospital supplies market is estimated to register a CAGR of approximately 7% during the forecast period, 2018 to 2023. Hospital medical equipment and supplies include various devices, tools, instruments, and medical consumables that are used in hospitals and healthcare establishments.Increasing Awareness about HospitalAcquired Infections HAIsThe rise in incidences of infections an...

Asterias gains exclusive license to stroke IP from University of California

Asterias Biotherapeutics Inc. obtained from the Regents of the University of California an exclusive license covering rights ...

Biotech Report: MagForce und Vita34 fester, Amgen gesucht

(shareribs.com) Frankfurt / New York 13.07.2018 - Biotech-Aktien zeigten sich am Freitag in Frankfurt überwiegend fester. Unter Druck lagen die Papiere von Santhera und BB Biotech. An der Wall Stre...

Lead Author Reflects on LILAC Study of Trastuzumab Biosimilar ABP 980

Hans-Christian Kolberg, MD, discusses ABP 980 and the future of biosimilars in oncology.

Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review

As Amgen’s main hope for extending its bone health franchise, romosozumab faces a second review at the FDA with a...   

With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug

More than a year after the FDA rejected Amgen’s experimental osteoporosis drug due to safety concerns, the Thousand Oaks, CA, company has teed up a new application. The Amgen (NASDAQ: AMGN) drug, romosozumab (Evenity), is an antibody treatment meant to strengthen bones and reduce the chance that they could break. But while romosozumab did lower […]

Morgan Stanley hebt Ziel für Amgen auf 210 Dollar - 'Overweight'

Die US-Investmentbank Morgan Stanley hat das Kursziel für Amgen von 200 auf 210 US-Dollar angehoben und die Einstufung auf "Overweight" belassen. Anlass der Studie ist eine Wiedervorlage des Medik...

Jefferies belässt Amgen auf 'Buy' - Ziel 200 US-Dollar

Das Analysehaus Jefferies hat die Einstufung für die Aktien des Biotechnologiekonzerns Amgen auf "Buy" mit einem Kursziel von 200 US-Dollar belassen. Dies geht aus einer am Freitag vorliegenden St...

Amgen and UCB Resubmit BLA for Evenity to the FDA for the Treatment of Osteoporosis

THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for ...

Amgen, UCB again seeking FDA nod for osteoporosis mAb

Global Electrophysiology Market Segmented by Type of Product and Geography Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $4250

The global electrophysiology market has been estimated to register a CAGR of 6.5% during the forecast period 2018 to 2023. Although North America dominates the market due to increasing incidences of heart failure and rapid technological advancements, APAC is expected to register the highest CAGR due to increasing cases of arrhythmia and high adoption rates in emerging market.Growing Incidence of A...

Pharma Q2 Results Preview: Johnson & Johnson And Novartis

The earnings season is on us again with two of the heavyweights of healthcare hoping to show strong second-quarter results...    

Asterias gains patent rights for method to improve stroke recovery

Asterias Biotherapeutics has obtained exclusive rights to a University of California-owned patent family for a process relate -More- 

Gilenya patent decision gives MS market a reprieve

A favorable decision from an IPR hearing could delay a generic version of Novartis' oral multiple sclerosis drug, potentially helping rivals as well. 

Biosimilars: implications for oncologists

In 2015, the US Food and Drug Administration (FDA) approved its first biosimilar, filgrastim-sndz, a biosimilar of the granulocyte colony-stimulating factor filgrastim. Since then, FDA has approved four additional biosimilar tumour necrosis factor α inhibitors, and in May 2017, the Oncology Drug Advisory Committee voted in favour of approval of an epoetin alfa biosimilar. Three biosimilar monoclo...

Analytical consideration in demonstrating similarity for biosimilars

According to the US Food and Drug Administration (FDA) guideline on ‘Scientific Considerations in Demonstrating Biosimilarity to a Reference Product’ [1], ‘FDA expects that first, a sponsor will extensively characterize the proposed product and the reference product with state‐of‐the‐art technology, because extensive characterization of both products serves as the foundation for a demo...

Hatch aims to promote biosimilars and generics and restrict litigation

Senator Orrin Hatch filed an amendment to the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which was advanced to the Senate by the Judiciary Committee on 14 June 2018.

Positive results for infliximab and trastuzumab biosimilars

Celltrion Healthcare (Celltrion) and Samsung Bioepis have both announced positive results for their infliximab and trastuzumab biosimilars, respectively.

US pharmacies sue J&J for stifling infliximab biosimilars

Two major US pharmacy chains, Walgreen and Kroger, have sued healthcare giant Johnson & Johnson (J&J) in the US District Court Eastern District of Pennsylvania. The pharmacies allege that J&J prevented insurers from covering biosimilars of its blockbuster immunology drug Remicade (infliximab).

Amgen, UCB Resubmit BLA

For EVENITY for the treatment of osteoporosis in postmenopausal women at high risk for fracture

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the tr...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks